Company
MindMed
NASDAQ:MNMD
MindMed is a clinical-stage psychedelic medicine biotech company that discovers, develops and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including psilocybin, LSD, MDMA, DMT, mescaline and an Ibogaine derivative, 18-MC. The MindMed executive team brings extensive biopharmaceutical experience to MindMed’s approach to developing the next generation of psychedelic inspired medicines and therapies.
6 stories
MindMed price target lowered by Canaccord analysts after Phase 2a US clinical trial shelved
“With an implied more than 500% of potential upside from current levels and considering MNMD is trading below cash value of US$4 per share, we reiterate our 'Speculative Buy' rating,” the analysts wrote